repetitive portion, can differ from each other in aspects such as geographical distribution,
intensity of transmission, vectorial competence and immune response. Such aspects must
be considered to P. vivax vaccine development. Therefore, we evaluated the
immunogenicity of novel recombinant proteins corresponding to each of the three P. vivax
allelic variants (VK210, VK247 and P. vivax-like) and of the C-terminal region (shared by all …